Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A

Pierluigi Macchioni, Luigi Boiardi, Riccardo Meliconi, Lia Pulsatelli, Mario Casadei Maldini, Romina Ruggeri, Andrea Facchini, Carlo Salvarani

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate the levels of serum chemokines in patients with psoriatic arthritis (PsA) before and during cyclosporin A (CyA) treatment. Methods. Sixteen outpatients with active PsA were followed for 6 months during low dosage CyA treatment. Serum chemokines of the C-X-C and C-C groups were determined by ELISA at the baseline. Serum RANTES levels were measured at 2 month intervals for 6 months. Serum chemokine levels were related with clinical and laboratory disease activity variables. Results. Serum interleukin 8 and macrophage inflammatory protein 1α levels were undetectable at baseline. Mean serum growth related gene product-α and monocyte chemoattractant protein 1 values were reduced and serum RANTES were elevated compared to controls. CyA treatment did not change serum RANTES levels. Patients with PsA with persistently normal serum RANTES levels (4 patients) had a more favorable clinical and laboratory response to CyA compared to patients with persistently high serum levels (6 patients). Conclusion. Serum RANTES levels are higher in patients with PsA than in a control population. CyA treatment does not change RANTES values. Patients with PsA with persistently normal RANTES levels have a better response to CyA treatment.

Original languageEnglish
Pages (from-to)320-325
Number of pages6
JournalJournal of Rheumatology
Volume25
Issue number2
Publication statusPublished - Feb 1998

    Fingerprint

Keywords

  • Chemokines
  • Cyclosporin A
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Macchioni, P., Boiardi, L., Meliconi, R., Pulsatelli, L., Maldini, M. C., Ruggeri, R., Facchini, A., & Salvarani, C. (1998). Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A. Journal of Rheumatology, 25(2), 320-325.